摘要:
A composition including a) 55-98.9 wt % of at least one type of triblock copolymer (A) of formula (1) R—B-A-B—R (1) b) 0.1-15 wt % of at least one surfactant (B) and c) 1-30 wt % of water, wherein A is a hydrophilic block having a number average molecular weight (Mn) of 100-1,000 Da, B is a hydrophobic block made from monomers having at least a monomer B1 and a monomer B2, wherein B1 and B2 have the largest weight contents in the hydrophobic block and B1 has a lower molecular weight than B2, wherein R is an end group which is H or a C1-C30 organic moiety, wherein the composition is fluid in a temperature range of 0° C. to 37° C., wherein the weight % are relative to the sum of a), b) and c), and wherein the sum of components a), b) and c) is at least 80 wt % of the entire composition, preferably at least 90 wt %; to the use of the composition and to pharmaceutical composiitons having said composition and an active pharmaceutical ingredient.
摘要:
Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.
摘要:
A composition including a) 55-98.9 wt % of at least one type of triblock copolymer (A) of formula (1) R—B-A-B—R (1) b) 0.1-15 wt % of at least one surfactant (B) and c) 1-30 wt % of water, wherein A is a hydrophilic block having a number average molecular weight (Mn) of 100-1,000 Da, B is a hydrophobic block made from monomers having at least a monomer B1 and a monomer B2, wherein B1 and B2 have the largest weight contents in the hydrophobic block and B1 has a lower molecular weight than B2, wherein R is an end group which is H or a C1-C30 organic moiety, wherein the composition is fluid in a temperature range of 0° C. to 37° C., wherein the weight % are relative to the sum of a), b) and c), and wherein the sum of components a), b) and c) is at least 80 wt % of the entire composition, preferably at least 90 wt %; to the use of the composition and to pharmaceutical compositions having said composition and an active pharmaceutical ingredient.
摘要:
A bioresorbable triblock copolymer according to Formula 1 R-B-A-B-R (1) wherein A is a hydrophilic polymer, B a hydrophobic polymer and R are end-groups, wherein R is H or a C1-C30 organic moiety and wherein the copolymer is fluid in a temperature range of 0° C. to 37° C. A pharmaceutical composition including the triblock copolymer and at least one therapeutically active agent. The copolymer and pharmaceutical composition can be used for forming a depot in a human or animal body or as medical device.
摘要:
A bioresorbable triblock copolymer according to Formula 1 R-B-A-B-R (1) wherein A is a hydrophilic polymer, B a hydrophobic polymer and R are end-groups, wherein R is H or a C1-C30 organic moiety and wherein the copolymer is fluid in a temperature range of 0° C. to 37° C. A pharmaceutical composition including the triblock copolymer and at least one therapeutically active agent. The copolymer and pharmaceutical composition can be used for forming a depot in a human or animal body or as medical device.
摘要:
Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (Mn) of between 900 and 3000 Daltons, determined with size exclusion chromatography; wherein B are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each B-block having a number average molecular weight (Mn) of between 400 and 2000 Daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a C2-C20 fatty acid. The invention also relates to compositions with such polymers and the use thereof.